Font Size: 

Current methods to evaluate the severity and progression of the disease, effectiveness of therapy and survival among cancer patients are generally limited in their prognostic ability. Whole-body phase angle, measured by using a tetrapolar, phase-sensitive bioelectrical impedance analyzer, offers a new approach. Phase angle (arc tangent of the ratio of reactance to resistance) is a non-invasive measurement of tissue bioelectrical properties. Findings from observational studies reveal that phase angle is an independent indicator of prognosis in cancer because it illustrates cell membrane integrity and function that are not possible with other measurement approaches. We propose a phase angle-based biometric scoring system for prognosis in cancer. Phase angle measurements outside the range of normal values indicate categorical states (frailty and morbidity) with the severity based on magnitude and rate of diminution of the phase angle value compared to the early diagnosis value. Change in the rate of ascent, plateau and decline of the phase angle indicate impact of therapy throughout the clinical intervention and may provide significant additional prognostic information in support of improved decision making. Thus, phase angle immediately offers a safe, practical, economical, FDA-approved device and a unique biometric scoring system into the clinical practice of cancer treatment.